| dc.description.abstract | Streptococcus pneumoniae (Klein, 1884) can cause disease with high morbidity and mortality in children under
2 yr of age, parents, and individuals with low immunity. Amount one of the diseases that can be caused by these
bacteria is pneumonia. To prevent the spread of pneumonia, intranasal immunization has been developed in several
studies because of its ability to improve mucosal and systemic immune responses. To prevent the attachment of
bacteria to the epithelial surface of the respiratory tract, it would be more effective if intranasal immunization uses
a vaccine from bacterial pili protein. The purpose of this study was to conducted to determine the ability of
S. pneumoniae bacterial pili protein with a molecular weight of 54 kDa in increasing the concentration of mucosal
and systemic antibodies through intranasal administration. Setting and design in this study using pure 54 kDa pili
protein was used as an antigen to immunize Wistar mice. Mucosal antibodies were identified by the presence of
sIgA in nasal washings and systemic antibodies determined from serum IgA and IgG. Statistical analysis used
ANOVA. Mice immunized with combination adjuvant–antigens had higher levels of sIgA, IgA, and IgG than other
groups. ANOVA statistical tests showed significant differences in sIgA and IgA levels between rats immunized
with antigen–adjuvants and other groups. However, there is no significant difference from serum IgG. This study
showed an intranasal immunization of 54 kDa hemagglutinin pili protein S. pneumoniae increased the
concentration of sIgA, serum IgA and IgG. | en_US |
